{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T21:32:46Z","timestamp":1789162366874,"version":"build-2803163510"},"reference-count":47,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["N01-PC-54405"],"award-info":[{"award-number":["N01-PC-54405"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["NO1-PC-35138"],"award-info":[{"award-number":["NO1-PC-35138"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["N01-PC-35145"],"award-info":[{"award-number":["N01-PC-35145"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["N01-PC-35137"],"award-info":[{"award-number":["N01-PC-35137"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["N01-PC-35142"],"award-info":[{"award-number":["N01-PC-35142"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["N01-PC-35143"],"award-info":[{"award-number":["N01-PC-35143"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["N01-PC-35139"],"award-info":[{"award-number":["N01-PC-35139"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["N01-PC-35136"],"award-info":[{"award-number":["N01-PC-35136"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["N01-PC-54404"],"award-info":[{"award-number":["N01-PC-54404"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["N01-PC-35135"],"award-info":[{"award-number":["N01-PC-35135"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["N01-PC-35133"],"award-info":[{"award-number":["N01-PC-35133"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["N01-PC-35141"],"award-info":[{"award-number":["N01-PC-35141"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["N01-PC-54402"],"award-info":[{"award-number":["N01-PC-54402"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1016\/j.amjmed.2010.03.018","type":"journal-article","created":{"date-parts":[[2010,7,28]],"date-time":"2010-07-28T08:40:51Z","timestamp":1280306451000},"page":"764.e1-764.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Age Disparity in the Dissemination of Imatinib for Treating Chronic Myeloid Leukemia"],"prefix":"10.1016","volume":"123","author":[{"given":"Charles L.","family":"Wiggins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda C.","family":"Harlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold E.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl L.","family":"Willman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward N.","family":"Libby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Hromas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2010.03.018_bib1","series-title":"Cancer Epidemiology and Prevention","first-page":"841","article-title":"The leukemias","author":"Linet","year":"2006"},{"key":"10.1016\/j.amjmed.2010.03.018_bib2","series-title":"Cancer Facts & Figures 2008","first-page":"4","year":"2008"},{"key":"10.1016\/j.amjmed.2010.03.018_bib3","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrc2368","article-title":"Getting to the stem of chronic myeloid leukaemia","volume":"8","author":"Savona","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.amjmed.2010.03.018_bib4","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.amjmed.2010.03.018_bib5","first-page":"478","article-title":"New insights in biology and current therapeutic options for patients with chronic myelogenous leukemia","volume":"82","author":"Carella","year":"1997","journal-title":"Haematologica"},{"key":"10.1016\/j.amjmed.2010.03.018_bib6","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/1097-0142(20001015)89:8<1647::AID-CNCR1>3.0.CO;2-U","article-title":"Therapeutic choices in younger patients with chronic myelogenous leukemia","volume":"89","author":"Kantarjian","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.amjmed.2010.03.018_bib7","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of BCR-ABL positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.amjmed.2010.03.018_bib8","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1182\/blood.V90.9.3691","article-title":"The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells","volume":"90","author":"Deiniger","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.amjmed.2010.03.018_bib9","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2010.03.018_bib10","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2010.03.018_bib11","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2010.03.018_bib12","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2010.03.018_bib13","series-title":"Approval Letter for Application Number NDA 21-335","year":"2001"},{"key":"10.1016\/j.amjmed.2010.03.018_bib14","first-page":"1972","article-title":"Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase","volume":"9","author":"Cohen","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.amjmed.2010.03.018_bib15","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.3324\/haematol.13045","article-title":"Recent trends in long-term survival of patients with chronic myelocytic leukemia: disclosing the impact of advances in therapy on the population level","volume":"93","author":"Brenner","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.amjmed.2010.03.018_bib16","first-page":"1671","article-title":"Trends in adult leukemia incidence and survival in Denmark, 1943-2003","volume":"20","author":"Thygesen","year":"2009","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.amjmed.2010.03.018_bib17","first-page":"1117","article-title":"The Surveillance, Epidemiology, and End Results program: a national resource","volume":"8","author":"Hankey","year":"1999","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.amjmed.2010.03.018_bib18","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1146\/annurev.publhealth.18.1.341","article-title":"Measuring social class in US public health research: concepts, methodologies, and guidelines","volume":"18","author":"Krieger","year":"1997","journal-title":"Annu Rev Public Health"},{"key":"10.1016\/j.amjmed.2010.03.018_bib19","series-title":"Rural-Urban Continuum Codes for Metro and Non-Metro Counties, 1993","author":"Butler","year":"1994"},{"key":"10.1016\/j.amjmed.2010.03.018_bib20","series-title":"Survival Models and Data Analysis","author":"Elandt-Johnson","year":"1980"},{"key":"10.1016\/j.amjmed.2010.03.018_bib21","series-title":"Analysis of Survival Data","author":"Cox","year":"1984"},{"key":"10.1016\/j.amjmed.2010.03.018_bib25","series-title":"SEER*Stat Software, Version 6.4.4","year":"2008"},{"key":"10.1016\/j.amjmed.2010.03.018_bib26","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z","article-title":"Permutation tests for Joinpoint regression with applications to cancer rates","volume":"19","author":"Kim","year":"2000","journal-title":"Stat Med"},{"key":"10.1016\/j.amjmed.2010.03.018_bib27","series-title":"Joinpoint Regression Program, Version 3.2.0","year":"2008"},{"key":"10.1016\/j.amjmed.2010.03.018_bib28","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/cncr.11629","article-title":"Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia","volume":"98","author":"Cortes","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.amjmed.2010.03.018_bib29","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1200\/JCO.2000.18.7.1412","article-title":"Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII","volume":"18","author":"Crivellari","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjmed.2010.03.018_bib30","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.ctrv.2005.04.012","article-title":"Cancer in the older person","volume":"31","author":"Carreca","year":"2005","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.amjmed.2010.03.018_bib31","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1200\/JCO.2006.10.4208","article-title":"Older female cancer patients: importance, causes, and consequences of undertreatment","volume":"25","author":"Bouchardy","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjmed.2010.03.018_bib32","doi-asserted-by":"crossref","first-page":"M46","DOI":"10.1093\/geronj\/44.2.M46","article-title":"Age as a predictor of diagnostic and initial treatment intensity in newly diagnosed breast cancer patients","volume":"44","author":"Silliman","year":"1989","journal-title":"J Gerontol"},{"key":"10.1016\/j.amjmed.2010.03.018_bib33","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1002\/cncr.11110","article-title":"Can older cancer patients tolerate chemotherapy?","volume":"97","author":"Chen","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.amjmed.2010.03.018_bib34","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S1470-2045(02)00730-1","article-title":"A case for geriatric oncology","volume":"3","author":"Repetto","year":"2002","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.amjmed.2010.03.018_bib35","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1056\/NEJM199912303412706","article-title":"Under-representation of patients 65 years of age or older in cancer-treatment trials","volume":"341","author":"Hutchins","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2010.03.018_bib36","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1200\/JCO.2003.12.044","article-title":"Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier?","volume":"21","author":"Yee","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjmed.2010.03.018_bib37","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1200\/JCO.2005.01.222","article-title":"Improving accrual of older persons to cancer treatment trials: a randomized trial comparing an educational intervention with standard information: CALGB 360001","volume":"23","author":"Kimmick","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjmed.2010.03.018_bib38","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1200\/JCO.2005.00.141","article-title":"Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials","volume":"23","author":"Townsley","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjmed.2010.03.018_bib39","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1023\/A:1008327129699","article-title":"Oncology healthcare professionals' attitudes toward elderly people","volume":"11","author":"Kearney","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1016\/j.amjmed.2010.03.018_bib40","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/0140-6736(90)91075-L","article-title":"Cancer in the elderly: why so badly treated?","volume":"335","author":"Fentiman","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2010.03.018_bib41","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/j.1532-5415.2004.52312.x","article-title":"Breast cancer treatment in older women: impact of the patient-physician interaction","volume":"52","author":"Maly","year":"2004","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.amjmed.2010.03.018_bib42","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ygyno.2004.05.033","article-title":"An assessment of age and other factors influencing protocol versus alternative treatments for patients with epithelial ovarian cancer referred to member institutions: a Gynecologic Oncology Group study","volume":"94","author":"Moore","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.amjmed.2010.03.018_bib43","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1471-2407-6-34","article-title":"Understanding the attitudes of the elderly towards enrolment into cancer clinical trials","volume":"6","author":"Townsley","year":"2006","journal-title":"BMC Cancer"},{"key":"10.1016\/j.amjmed.2010.03.018_bib44","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1056\/NEJMoa065901","article-title":"Radiotherapy for glioblastoma in the elderly","volume":"356","author":"Keime-Guibert","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2010.03.018_bib45","first-page":"39398","article-title":"Food and Drug Administration: November 1989 Guideline for the Study of Drugs Likely to Be Used in the Elderly","volume":"59","year":"1994","journal-title":"Fed Register"},{"key":"10.1016\/j.amjmed.2010.03.018_bib46","doi-asserted-by":"crossref","first-page":"572","DOI":"10.6004\/jnccn.2005.0032","article-title":"Senior adult oncology clinical practice guidelines in oncology","volume":"3","author":"Balducci","year":"2005","journal-title":"J Natl Comp Canc Netw"},{"issue":"Suppl 4","key":"10.1016\/j.amjmed.2010.03.018_bib47","first-page":"S1","article-title":"NCCN Task Force Report: breast cancer in the older woman","volume":"6","author":"Carlson","year":"2008","journal-title":"J Natl Comp Canc Netw"},{"key":"10.1016\/j.amjmed.2010.03.018_bib48","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1200\/JCO.2002.20.2.494","article-title":"Comprehensive geriatric assessment adds information to Eastern Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology study","volume":"20","author":"Repetto","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjmed.2010.03.018_bib49","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1177\/016224399502000402","article-title":"The construction of lay expertise: AIDS activism and the forging of credibility in the reform of clinical trials","volume":"20","author":"Epstein","year":"1995","journal-title":"Sci Technol Human Values"},{"key":"10.1016\/j.amjmed.2010.03.018_bib50","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nrc744","article-title":"Breast cancer activism: past lessons, future directions","volume":"2","author":"Lerner","year":"2002","journal-title":"Nat Rev Cancer"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934310003876?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934310003876?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:26:59Z","timestamp":1762079219000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934310003876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["S0002934310003876"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2010.03.018","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Age Disparity in the Dissemination of Imatinib for Treating Chronic Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2010.03.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. Published by Excerpta Medica Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}